Strikingly, at later time-point (i.e. 7 weeks after injection), immunostaining revealed that invasive tumor xenografts obtained upon injection of control MCF10DCIS.com cells expressed low NME1 levels, in contrast to in situ tumors that were frankly positive (Fig. 3E). The gene discussed is NME1; the disease is neoplasm.